Frost & Sullivan releases the 'Market Research Report on China's CRO Industry'

With the expiration of a large number of global drug patents, generic drugs are gradually squeezing out the patent drug market. In order to consolidate their market position and maintain profit growth, patent drug companies are continuously increasing their investment in new drug research and development. At the same time, drug regulatory laws around the world are becoming increasingly perfect, with stricter supervision over drug research and development. While improving drug safety, this has also greatly extended the R&D cycle for new drugs and increased R&D costs. With the support of these factors, the outsourcing industry for medical contract R&D services has broad prospects for the future. For this reason, based on research into this market, Frost & Sullivan (Frost & Sullivan) has released a relevant industry report.